EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Cirrhosis

Hatem Ahmed, Imad Alabdul Razzak, Eyad Abdulrazzak, Sameh Gomaa, Motaz Almahmood, Khloud Abdelrazeq, Joelle Lauchner

ASIDE Gastroenterology · 27.07.2026 · 2 (4) · 1-7

DOI: 10.71079/aside.gi.072726751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ASIDE Gastroenterology, online erschienen am 27.07.2026. Verfasst von Hatem Ahmed und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cirrhosis and metabolic comorbidities frequently coexist. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown cardiometabolic and hepatic benefits, but their comparative effectiveness in established cirrhosis remains unclear. We compared 1-year clinical outcomes between adults with cirrhosis initiating either class.

Methods

Using the TriNetX U.S. Collaborative Network, we identified adults with cirrhosis who initiated a GLP-1RA or SGLT2i after diagnosis and had no prior exposure to the comparator class. One-to-one propensity score matching balanced demographic, clinical, medication, and laboratory covariates. Primary outcomes at 1 year were all-cause mortality and inpatient hospitalization. Secondary outcomes included individual and composite cirrhosis decompensation events (ascites, paracentesis, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome) and adverse events (acute kidney injury, hypoglycemia, acute pancreatitis).

Results

The matched cohorts comprised 8,016 patients per arm. GLP-1RA users had lower 1-year all-cause mortality (4.3% vs 5.3%; OR 0.80, 95% CI 0.69–0.93; p=0.003) and fewer composite decompensation events (5.3% vs 6.7%; OR 0.78, 95% CI 0.69–0.88; p

Zitieren

APA

Ahmed, H., Razzak, I. A., Abdulrazzak, E., Gomaa, S., Almahmood, M., Abdelrazeq, K., & Lauchner, J. (2026). Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Cirrhosis. ASIDE Gastroenterology, 2(4), 1-7. https://doi.org/10.71079/aside.gi.072726751

Vancouver

Ahmed H, Razzak IA, Abdulrazzak E, Gomaa S, Almahmood M, Abdelrazeq K, et al. Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Cirrhosis. ASIDE Gastroenterology. 2026;2(4):1-7. doi:10.71079/aside.gi.072726751

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Hatem and Razzak, Imad Alabdul and Abdulrazzak, Eyad and Gomaa, Sameh and Almahmood, Motaz and Abdelrazeq, Khloud and Lauchner, Joelle},
  title = {Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Cirrhosis},
  journal = {ASIDE Gastroenterology},
  year = {2026},
  volume = {2},
  number = {4},
  pages = {1--7},
  doi = {10.71079/aside.gi.072726751}
}
Kostenlos starten →